Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

On May 28, 2024, Cytokinetics, Incorporated closed the transaction. The shares issued to investor were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act in a transaction not involving a public offering of such shares.